NHS England | June 2018 | NHS England strikes deal on new NICE recommended lung cancer immunotherapy drug
NHS England have announced it will make lung cancer drug pembrolizumab available for routine use on the NHS. Trial results show pembrolizumab extends life for certain adults with lung cancer for more than a year.
According to NHS England Pembrolizumab is the first drug to exceed the new budget impact threshold for new products costing more than £20 million a year. The drug, which is also called Keytruda, would have cost around £84,000 per patient at its full list price. NHS England and MSD have agreed a confidential arrangement for reimbursement which will enable NICE to recommend it be routinely available on the NHS (NHS England).
Royal College of Physicians | National Lung Cancer Audit 2017- Key findings for patients and carers | March 2018
The audit is a patient-focused report from the National Lung Cancer Audit (NLCA), commissioned by the Healthcare Quality Improvement Partnership (HQIP) on behalf of NHS England and the Welsh government.
It provides a a summary of key results from the 2017 National Lung Cancer Audit (NLCA) annual report, which looked at patients who were diagnosed with lung cancer during 2016. The results are based on data from 140 English NHS trusts and 13 Welsh hospital sites.
This booklet specifically looks at how organisations performed in key areas of the patient pathway. It does not include information on the types of treatment or drugs that are available to patients with lung cancer.
Further information is available from HQIP here
The full booklet can be accessed via HQIP
Full details of the findings are available from the Royal College of Physicians website
National Lung Cancer Audit annual report 2017 | The Healthcare Quality Improvement Partnership
This is the 13th annual report on the clinical component (process of care) of the National Lung Cancer Audit. It contains national and named team results on the quality of lung cancer care for patients diagnosed between 1 January and 31 December 2016 and covers many processes of care across the entire patient pathway.
Targeted audiences who will benefit from reading the findings of this report include NHS staff in lung cancer multidisciplinary teams; hospital managers and chief executives; commissioners; lung cancer researchers; lung cancer patients their families and their carers who may use the findings to inform their care decisions.
NHS England announces the scaling up of an innovative scheme that catches lung cancer early by scanning patients, along with new details of a more sensitive bowel cancer test that could save thousands of lives.
NHS England is now funding scanners in other areas as part of a national programme to diagnose cancer earlier, improve the care for those living with cancer and ensure each cancer patient gets the right care for them. This follows the success of the Manchester scanner scheme, where mobile scanners are detecting four out of five cases of lung cancer in the early stages when it is easier to treat. The mobile scanning trucks have picked up one cancer for every 33 patients scanned over the course of a year.
Plans for ‘FIT’, a more sensitive bowel cancer test that could see as many as 1,500 more cancer caught earlier every year have also been confirmed.
‘FIT’ is an easy to use home testing kit which predicts bowel cancer, following the introduction of the test almost a third of a million more people are expected to complete screening. The sensitivity level determines the number of people who should go on for further cancer testing.
National Lung Cancer Audit 2016: Key findings for patients and carers | The Healthcare Quality Improvement Partnership
The information in this booklet aimed at patients and carers is a summary of key results from the 2016 National Lung Cancer Audit (NLCA) annual report, which looked at patients diagnosed from 1 January to 31 December 2015. This booklet specifically looks at how the organisation performed in key areas of the patient pathway. It does not include information on the types of treatment or drugs available to lung cancer patients.
Neal, R.D. et al. (2017) British Journal of Cancer. 116, pp. 293-302
Background: Achieving earlier stage diagnosis is one option for improving lung cancer outcomes in the United Kingdom. Patients with lung cancer typically present with symptoms to general practitioners several times before referral or investigation.
Conclusions: We have demonstrated the feasibility of individually randomising patients at higher risk of lung cancer, to a trial offering urgent investigation or usual care.